This study is looking at how Ferric Citrate (Auryxia®) affects children aged 6 to 18 with chronic kidney disease (CKD) stages 3-4. We want to see if Ferric Citrate can change levels of a protein called iFGF23, which is important in kidney health. Participants will receive either Ferric Citrate or a placebo (an inactive pill that looks the same) for 12 months. We're also checking the safety and how well children tolerate Ferric Citrate. To join, your child needs to be between 6 and 18 years old, have a specific kidney function level (GFR of 15-59 ml/min per 1.73 m2), and have certain blood test results for phosphate, ferritin, and TSAT. We plan to enroll 160 children in total.

Study design

This is a double-blind, randomized, placebo-controlled study involving 160 participants. Participants will be randomly assigned to receive either Ferric Citrate or a placebo.

What's involved

Participants will take a daily dose of Ferric Citrate or placebo for 12 months. Blood samples for primary outcome assessments will be collected at screening, baseline, and at months 3, 6, 9, and 12. Blood for safety assessments will be collected at months 1, 2, 3, 6, 9, and 12.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for this study are measured at 12 months, which is the duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.